A North Carolina-based pharmaceutical company raised over $1.8 million in equity, according to a filing with the Securities and Exchange Commission.

Durham-based Renovion Inc. filed a Form D signed by Daniel Copeland, Joseph Davis, R. McCoy Jr. and Derek Winstanly on Jan 17.

According to its website, Renovion is pre-clinical stage pharmaceutical company with a therapy for chronic inflammatory airway diseases. The company is working to create a drug to get approved to help those who have received a bilateral lung transplant.

The company also wants to develop therapies for cystic fibrosis, asthma, and chronic obstructive pulmonary disease.

The total filing is for $2,051,000 and $1,868,936 has been raised so far from 13 investors.

This is an amended notice with the first date of sale on Aug. 11, 2016. This offer is not being made in connection with a business combination transaction. There is no minimum investment accepted from an outside advisor.

None of the money raised will be used for payment to executive directors other than the payments of the salary in the ordinary course of business to certain of the parties listed on the filing.

The company claimed a Rule 506 (b) exemption for the filing. Companies relying on the Rule 506 exemption do not have to register their offering of securities with the SEC, but they must file what’s known as a Form D electronically with the SEC after they first sell their securities.